## **Supplementary Material**

## Chrysin Inhibits Proinflammatory Factor-Induced EMT Phenotype and Cancer Stem Cell-Like Features in HeLa Cells by Blocking the NFκB/Twist Axis

Weilei Dong<sup>a</sup> A Chen<sup>b</sup> Xiaocheng Cao<sup>b</sup> Xiang Li<sup>b</sup> YingHong Cui<sup>b</sup> Chang Xu<sup>b</sup> Jianguo Cao<sup>b</sup> Yingxia Ning<sup>c</sup>

<sup>a</sup>Department of Obstetrics and Gynecology, The First Affiliated Hospital, University of South China, Hengyang, <sup>b</sup>Department of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, Key Laboratory of Study and Discover of Small Targeted Molecules of Hunan Province, Changsha, <sup>c</sup>Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

## **Supplementary Figure Legends**




Figure S1 Comparison of xenograft tumor growth in nude mouse models inoculated with TNF- $\alpha$ /TGF- $\beta$  co-treated and control HeLa cells

A: Tumor-bearing nude mice were photographed. Control HeLa cells were subcutaneously transplanted near the left forelimb, while those co-treated with TNF- $\alpha$  and TGF- $\beta$  were subcutaneously transplanted near the right forelimb. Subcutaneously transplanted tumors from the nude mice were imaged: upper row, HeLa cells treated with TNF- $\alpha$  combined with TGF- $\beta$ ; lower row, control HeLa cells.

B: Comparison of xenograft volumes in nude mouse models inoculated with TNF- $\alpha$ /TGF- $\beta$  co-treated and the control HeLa cells.

C: Comparison of xenograft weights in nude mouse models inoculated with TNF- $\alpha$ /TGF- $\beta$  co-treated and the control HeLa cells.

D: H&E staining of subcutaneous xenografts from nude mouse models inoculated with TNF- $\alpha$ /TGF- $\beta$  co-treated and control HeLa cells.




Figure S2 Effects of ChR on the NF- $\kappa B$  DNA binding activities of HeLa cells co-treated with TNF- $\alpha$  and TGF- $\beta$  at different time points.

10.0 μM ChR treatment significantly reduced DNA binding activity of NF-κBp65 at 3 h, 6 h, 12 h and 24 h, as compared with the same time points in vector (0.1% DMSO) control. \*P<0.05, treatment with 0.1% DMSO or ChR (10.0 μM) at 0.5h, 3.0 h, 6.0 h, 12.0h and 24 h compared to treatment with 0.1% DMSO or ChR (10.0 μM) at 0 h co-treated with TNF- $\alpha$  and TGF- $\beta$ ; \*P<0.05, treatment with 0.1% DMSO compared to treatment with ChR (10.0 μM) co-treated with TNF- $\alpha$  and TGF- $\beta$  at the same time points.




Figure S3 Immunofluorescence of HeLa cells expressing GFP and NF-κBp65 shRNA (magnification: ×20)




Figure S4 Immunofluorescence of HeLa cells expressing GFP and NF-κBp65 cDNA (magnification: ×20)




Figure S5 Immunofluorescence of HeLa cells expressing GFP and Twist1 shRNA (magnification: ×20)




Figure S6 Immunofluorescence of HeLa cells expressing GFP and Twist1 cDNA (magnification:  $\times 20$ )